Eurofins Scientific SE (Eurofins Scientific SE) Long-Term Capital Lease Obligation : $476 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Eurofins Scientific SE Long-Term Capital Lease Obligation?

Eurofins Scientific SE's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $476 Mil.

Eurofins Scientific SE's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 ($423 Mil) to Jun. 2023 ($440 Mil) and increased from Jun. 2023 ($440 Mil) to Dec. 2023 ($476 Mil).

Eurofins Scientific SE's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($473 Mil) to Dec. 2022 ($423 Mil) but then increased from Dec. 2022 ($423 Mil) to Dec. 2023 ($476 Mil).

Eurofins Scientific SE Long-Term Capital Lease Obligation Historical Data

The historical data trend for Eurofins Scientific SE's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eurofins Scientific SE Long-Term Capital Lease Obligation Chart

Eurofins Scientific SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

489.11

504.62

472.54

422.67

475.57

Eurofins Scientific SE Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															472.54	418.50	422.67	440.09	475.57

Eurofins Scientific SE (OTCPK:ERFSF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Eurofins Scientific SE Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Eurofins Scientific SE's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eurofins Scientific SE (Eurofins Scientific SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Eurofins Scientific SE (OTCPK:ERFSF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ERFp:UK 0MV5:UK ERF:France ESF0:Germany

Address

23 Val Fleuri, Luxembourg, LUX, L-1526

Website

https://www.eurofins.com

Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 900 laboratories in 61 countries. Its revenue from Europe, North America, and the Rest of the World contribute approximately 50%, 40%, and 10% of total revenue respectively. Its main business activities are food and environmental testing, biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.